2024-05-07 17:17:19 ET
Summary
- Medicenna is a Canadian biotech company developing Superkines, enhanced cytokine drugs, in oncology.
- Their lead asset, MDNA-11, showed promising results in a Phase 1/2 study for refractory cancers, including a monotherapy partial response in pancreatic cancer.
- Bizaxofusp, an IL-4 Superkine, demonstrated compelling results in glioblastoma, with increased median overall survival compared to the control arm.
- The company will present the updated data from MDNA-111 monotherapy cohorts and combination cohorts (with Keytruda) for the Phase 1/2 Abilify study at in advanced/metastatic refractory solid tumors at the upcoming ASCO conference in June.
Medicenna Therapeutics Corp. ( MDNAF , MDNA.CA) is a Canadian biotech company that is developing Superkines (enhanced cytokine drugs) in oncology....
Read the full article on Seeking Alpha
For further details see:
New Buy, Medicenna: Superkine Platform In Oncology